|
業務類別
|
Biotechnology |
|
業務概覽
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
| 公司地址
| 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709 |
| 電話號碼
| +1 302 274-8744 |
| 傳真號碼
| +1 604 737-7077 |
| 公司網頁
| https://www.zymeworks.com |
| 員工數量
| 264 |
| Mr. Sabeen Mekan |
Senior Vice President and Chief Medical Officer |
-- |
02/03/2026 |
| Mr. Kenneth Galbraith |
Chairman of the Board, Chief Executive Officer and President |
美元 654.83K |
01/04/2026 |
| Dr. Paul Andrew Moore, PhD |
Chief Scientific Officer |
美元 494.68K |
02/03/2026 |
| Ms. Kristin Stafford, C.P.A. |
Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
-- |
01/04/2026 |
| Mr. Mark Hollywood |
Executive Vice President and Chief Operating Officer |
-- |
12/01/2026 |
|
|
| Mr. Robert E. Landry |
Director |
02/03/2026 |
| Dr. Susan Mahony, M.B.A.,PhD |
Lead Independent Director |
02/03/2026 |
| Mr. Oleg Nodelman |
Independent Director |
02/03/2026 |
| Mr. Kenneth Galbraith |
Chairman of the Board, Chief Executive Officer and President |
01/04/2026 |
| Dr. Kelvin M. Neu, M.D. |
Independent Director |
02/03/2026 |
| Mr. Brian N. Cherry |
Director |
12/01/2026 |
| Mr. Carlos E. Campoy |
Independent Director |
02/03/2026 |
| Mr. Gregory A. Ciongoli |
Director |
02/03/2026 |
| Dr. Alessandra Cesano, M.D. |
Independent Director |
02/03/2026 |
|
|
|
|
